LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1
- 1 May 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 71 (9) , 1287-1294
- https://doi.org/10.1097/00007890-200105150-00018
Abstract
Immunosuppressive treatment in transplant patients frequently causes infectious complications with cytomegalovirus (CMV). The extent of CMV replication can be followed by a number of diagnostic methods. There is, however, no simple diagnostic tool to assess the quality of the cellular antiviral immune response of an individual patient. This would be of particular importance for therapy decisions, as patients with detectable virus load do not necessarily develop CMV-related disease. Using a rapid whole blood assay, the frequencies of CMV-reactive CD4 and CD8 T cells were followed after renal transplantation to characterize their relative contribution in the containment of CMV infection. T cells from transplant patients and healthy control persons were stimulated with CMV antigen in vitro. Based on specific cellular activation and induction of intracellular cytokines, the frequency of CMV-reactive CD4 and CD8 T cells was determined using flow cytometry. Viral load was quantified using the “hybrid-capture” assay. The absence of CMV complications in long-term transplant recipients is reflected by stable virus-specific T-cell frequencies, which do not differ from healthy CMV-positive controls. In contrast, during the first months after transplantation, clinical symptoms are preceded by a decrease in CMV-reactive CD4 T-cell frequencies and an increase in CMV load. The individual immune response and CMV replication are critically balanced and can be characterized by assessing both viral load and antiviral T cells. Our experimental design allows the identification of patients with sufficient, insufficient, or absent T-cell activity and can serve as diagnostic tool to facilitate decisions on antiviral therapy.Keywords
This publication has 21 references indexed in Scilit:
- Cytomegalovirus (CMV)–Specific T Cell Immunity after Renal Transplantation Mediates Protection from CMV Disease by Limiting the Systemic Virus LoadThe Journal of Infectious Diseases, 1999
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- Antiviral DrugsNew England Journal of Medicine, 1999
- Hierarchical and Redundant Lymphocyte Subset Control Precludes Cytomegalovirus Replication during Latent InfectionThe Journal of Experimental Medicine, 1998
- Infection in Organ-Transplant RecipientsNew England Journal of Medicine, 1998
- Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV diseaseBone Marrow Transplantation, 1997
- Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the DonorNew England Journal of Medicine, 1995
- Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.The Journal of Experimental Medicine, 1994
- Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes.The Journal of Experimental Medicine, 1989
- THE ROLE OF PRETRANSPLANT IMMUNITY IN PROTECTION FROM CYTOMEGALOVIRUS DISEASE FOLLOWING RENAL TRANSPLANTATIONTransplantation, 1985